Eugenio Aringhieri is Chief Executive Officer of the Italian biopharmaceutical Dompé Group.
Since 2007, in line with the wishes of its owner, he has promoted the company’s functional reorganisation and given impulse to its industrial strategy with the aim of making the Group an internationally recognised science-based company.
To this end, in 2008, he consolidated its partnership with Amgen by creating Amgen Dompé, a parithetic joint venture of which he was President, and established the strategic programme and priority objectives of Biogen Dompé, a parithetic joint venture - of which he has been CEO - with Biogen Idec, the world’s leading biotech company, thus consolidating their initial marketing agreement into a partnership by creating a new company in Italy and Switzerland.
He also further strengthened the Group’s commitment to research, and promoted a strategy of investing in companies capable of dynamically contributing to therapeutic innovation.
In 2010, he was nominated Vice-President of the Board of Directors of Philogen, an Italo-Swiss biotech company dedicated to developing products for the treatment of cancer, rheumatoid arthritis and some eye diseases, of which Dompé is the leading shareholder.
In 2011, he joined the Board of Directors of AAA (Advanced Accelerator Applications), a leader in the field of molecular medicine that specialises in R&D, the production of radiopharmaceuticals for molecular imaging, and personalised medicine.
In the same year, he became President and Managing Director of Anabasis, an Italian biotech company that develops innovative drugs based on rhNGF (the discovery of which led to Prof. Rita Levi Montalcini being awarded the Nobel Prize) for the treatment of serious eye diseases for which no effective therapy is currently available, whose acquisition was completed in February 2012.
In 2015 Aringhieri was awarded as “Best CEO in Therapeutics Innovations Industry” at European CEO Awards, one of the most recognised prize for CEOs in Europe.
Since May 2016 he has been a member of the Board of Directors of e-Novia, a company focused on generating innovation for businesses through international research projects and partnerships.
Watch Eugenio Aringhieri's interview for European CEO
Since 2015, member of the Steering Committee of the University-Enterprise Observatory established at the CRUI (Conference of Italian University Rectors) Foundation
In 2014, he was nominated Farmindustria's representative on the National Committee for Biosafety, the Biotechnologies and the Life Sciences instituted by the office of the Italian Prime Minister.
In 2013, re-elected President of Farmindustria’s Biotech Group for a second consecutive mandate.
Since 2008, member of the International Board of European Biopharmaceutical Enterprises (EBE)
Since 2000, member of the Board of Governors of Farmindustria.
Eugenio Aringhieri is a Tuscan who graduated in Pharmacy from the University of Pisa.
Married, he has two children.